RecruitingPhase 3NCT06082102
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Studying Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Intervention
- Orelabrutinib(drug)
- Enrollment
- 324 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2030
Study locations (19)
- The First Affiliated Hospital of Bengbu Medical College, Bengbu, Auhui, China
- Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
- Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing Municipality, China
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
- Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Henan Provincial Peoples Hospital, Zhengzhou, Henan, China
- Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
- Hunan Cancer Hospital, Changsha, Hunan, China
- The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
- Jiangxi Cancer Hospital, Nanchang, Jiangxi, China
- The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
- The first Hospital of China Medical University, Shenyang, Liaoning, China
- The Affiliated Hospital Of Qingdao University, Qingdao, Shandong, China
- Yantai Yuhuangding Hospital, Yantai, Shandong, China
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06082102 on ClinicalTrials.govOther trials for Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07003295Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell TherapyNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT06875063GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHLThe First Affiliated Hospital of Xiamen University
- RECRUITINGNANCT07211048Anti CD19 Gene Therapy for B-cell LymphomaAnhui Provincial Hospital
- RECRUITINGPHASE1NCT07456371PIC1 Injection Therapy for Relapsed/Refractory B-NHLChongqing Precision Biotech Co., Ltd
- RECRUITINGNCT07147621Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological MalignanciesUniversity Hospital, Angers
- RECRUITINGNCT07546188AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients.Grand Hôpital de Charleroi
- RECRUITINGNCT07253129Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGNCT07374068Prognostic Model of Elderly Hodgkin Lymphoma in ChinaTianjin Medical University Cancer Institute and Hospital